Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
07 Fevereiro 2023 - 7:48PM
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and
innovator in seed brachytherapy and its newly merged partner
Viewpoint Molecular Targeting, Inc., today announced that they are
now doing business as Perspective Therapeutics, Inc., along with a
new brand identity effective immediately. Isoray, Inc. will change
its name to Perspective Therapeutics, Inc. by filing an amendment
to its Certificate of Incorporation as soon as possible.
Post-merger rebranding
highlights include:
- New tagline: “Treating cancers from the inside out”
- New corporate website
https://www.perspectivetherapeutics.com
- New NYSE American stock ticker symbol to be CATX, effective
February 21, 2023
“We believe that Perspective Therapeutics truly reflects
our potential to transform the field of precision oncology medicine
and the outcome of early-stage cancers through the advancement of
radiopharmaceuticals,” said Perspective Therapeutics, Inc. CEO
Thijs Spoor. “On behalf of Perspective Therapeutics board of
directors, employees and myself we look forward to bringing the
Company’s focus, as well as our commercial and strategic pipeline
development objectives to life.”
The Company currently trades on the NYSE American as Isoray,
Inc. under ticker symbol ISR which will change to Perspective
Therapeutics, Inc. with the ticker symbol of CATX on February 21,
2023.
Oppenheimer & Co. acted as Isoray’s financial advisor for
the merger transaction and Gallagher & Kennedy, P.A. served as
Isoray’s legal counsel. Sichenzia Ross Ference, LLP acted as
Viewpoint’s legal counsel.
About Perspective Therapeutics, Inc.Isoray,
Inc. (soon to operate as Perspective Therapeutics, Inc.) is a
medical technology and radiopharmaceutical company that is
pioneering advanced treatment applications for cancers throughout
the body. The Company is the sole producer of Cesium-131
brachytherapy seeds and has a proprietary technology that utilizes
the isotope lead-212 to deliver powerful alpha radiation
specifically to cancer cells via specialized targeting peptides.
The Company is also developing complementary imaging diagnostics
that incorporate the same targeting peptides which provide the
opportunity to personalize treatment and optimize patient outcomes.
This “theranostic” approach enables the ability to see the specific
tumor and then treat it to potentially improve efficacy and
minimize toxicity associated with many other types of cancer
treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor
(VMT-a-NET) programs are entering Phase 1/2a imaging and therapy
trials for the treatment of metastatic melanoma and neuroendocrine
tumors at several leading academic institutions. The Company has
also developed a proprietary lead-212 generator to secure isotope
supply for clinical trial and commercial operations. For more
information, please visit the Company’s website at
www.perspectivetherapeutics.com.
Safe Harbor StatementStatements in this news
release about Isoray’s future expectations, including those
regarding the name and ticker symbol change and all other
statements in this release, other than historical facts, are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (“PSLRA”). This statement
is included for the express purpose of availing Isoray of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as completion and timing of filing
an amendment to its Certificate of Incorporation in Delaware and
amendment of any agreements necessary to make effective the name
change and approval of the change in ticker symbol by the NYSE
American Exchange. Unless required to do so by law, we undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Isoray Investor Relations: Mark Levin (501) 255-1910
Viewpoint Investor Relations: Chuck Padala (941) 741-7792
Media and Public Relations: Sharon Schultz (302) 539-3747
IsoRay (AMEX:ISR)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
IsoRay (AMEX:ISR)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024